A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT)
Clinical trial NCT02303782 · WITHDRAWN
Trial details
- NCT number
- NCT02303782
- Sponsor
- Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- WITHDRAWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-01-01
- Primary completion
- 2016-03-01
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.